At a glance
ClinicalIndex Comparison Record- ✓Age > 18 years old
- ✓Resectable/borderline resectable/locally advanced pancreatic cancer per NCCN guidelines
- ✓ECOG performance status 0-2
- ✓Written informed consent provided
- ✕Prior thoracic or abdominal radiation therapy
- ✕Unable to receive SBRT at JHU
- ✕Duodenal invasion detected on imaging
- ✕Tumor located in pancreatic body or tail
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety Study of Intraoperative Radiation Therapy Following Stereotactic Body Radiation Therapy and Multi-agent Chemotherapy in the Treatment of Localized Pancreatic Adenocarcinoma
In Brief
A Phase 1 clinical trial evaluating High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT) for Pancreatic Cancer. Currently recruiting, targeting 25 participants across 1 site.
Detailed Summary
This study is designed to investigate the safety of intraoperative radiation therapy (IORT) in patients with localized pancreatic cancer undergoing surgical resection after neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT).
Study Details
Timeline
Interventions
After the patient receives standard of care treatment, they will receive a single dose of radiation (15 Gy) at the time the tumor is surgically removed. Surgeons will then place clips along the blood vessels around the surgical area. These clips will be used to confirm (after surgery) that the expected dose of radiation was received during surgery.